GWAS of Malignant Brain Tumors

We used summary data from a GWAS that was made public by the FinnGen consortium (Release 5, https://www.finngen.fi/en), including 464 cases and 174,006 controls for malignant brain tumors (all cancers excluded), 91 cases and 174,006 controls for brain glioblastoma (all cancers excluded) and 640 cases and 174,006 controls for malignant neoplasm of meninges (all cancers excluded).
All GWAS summary data on exposure and outcomes were based on the European population.

Free full text: Click here

Zhang Q., Wu G., Zhang X., Zhang J., Jiang M., Zhang Y., Ding L, & Wang Y. (2023). Vascular endothelial growth factor and risk of malignant brain tumor: A genetic correlation and two-sample Mendelian randomization study. Frontiers in Oncology, 13, 991825.

Publication 2023

Brain Cancers European Glioblastoma Gwas Malignant brain tumors Malignant neoplasm of meninges

Corresponding Organization : Beijing Shijitan Hospital

Other organizations : Beijing Sanbo Brain Hospital

Top 5 similar protocols

Variable analysis

independent variables

Not explicitly mentioned

dependent variables

Malignant brain tumors (all cancers excluded)
Brain glioblastoma (all cancers excluded)
Malignant neoplasm of meninges (all cancers excluded)

control variables

European population

controls

Not explicitly mentioned

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!